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Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely prescribed for   reduction 
of pain and inflammation, particularly in the setting of rheumatologic disorders. While 
  effective, they are associated with risks, including nephrotoxicity, gastrointestinal inflam-
mation, peptic ulcer disease, and worsened cardiovascular outcomes. After development of 
cyclo-oxygenase 2 inhibitors to minimize gastrointestinal complications, early use revealed 
increased cardiovascular event rate risk, and retrospective analysis of traditional NSAIDs 
revealed similar concerns, with the exception of naproxen. PN400 is a fixed-dose combination 
formulation designed to provide sequential delivery of a nonenteric-coated, immediate-release 
esomeprazole 20 mg mantle followed by an enteric-coated naproxen 500 mg core. This review 
summarizes the pharmacokinetics, benefits, safety, and tolerability of PN400. Phase I trials 
demonstrated pharmacokinetics consistent with its formulation, and at different esomeprazole 
combination doses, PN400 containing esomeprazole 20 mg was the lowest dose that still resulted 
in substantial sustained increases of gastric pH . 4. In two Phase III trials (Study 301 and Study 
302), PN400 resulted in a significant reduction in gastric ulcers relative to enteric-coated 
naproxen (4.1% to 23.1% in Study 301, 7.1% to 24.3% in Study 302). Discontinuation due to 
NSAID-associated upper gastrointestinal adverse events or duodenal ulcers was significantly 
less in PN400 patients (3.2% to 12%, P , 0.001, in Study 301; 4.8% to 11.9%, P = 0.009, in 
Study 302). Two subjective patient indices were utilized to assess tolerability, ie, the Severity 
of Dyspepsia Assessment (SODA) and Overall Treatment Evaluation of Dyspepsia (OTE-DP). 
Patients with PN400 had significantly better upper gastrointestinal tolerability compared with 
those treated with enteric-coated naproxen in terms of SODA scores, proportion of heartburn-
free patients, and OTE-DP response. While no formal recommendations are available at this 
time for use of this new combination medication, it will likely become an important treatment 
option with application for many patients.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most   commonly 
prescribed medications worldwide. Their indications for reduction of pain, 
inflammation, and fever extend to a wide variety of musculoskeletal and inflammatory 
disorders, including rheumatoid arthritis and osteoarthritis. Despite their therapeutic 
effectiveness, NSAIDs are associated with risks, including nephrotoxicity, worsened 
cardiovascular outcomes, gastrointestinal inflammation, and peptic ulcer disease, 
among others. As our understanding of the mechanisms and etiologies of NSAID-
induced gastrointestinal injury has grown, new therapies have been developed to 
minimize that toxicity. In development and evaluation of these new therapies, greater Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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cardiovascular toxicity has been appreciable, evident for 
both traditional NSAIDs and selective inhibitors. The newest 
  challenge has been seeking a balance with greatest benefit and 
least harm, often requiring a patient-individualized approach 
for these therapies.
Upper gastrointestinal complications are the most com-
mon risks of NSAID use. Resultant symptoms can include 
abdominal pain, diarrhea, dyspepsia, and gastrointestinal 
bleeding. Mucosal injury is mediated through a number 
of pathways, including an inhibition of cell proliferation, 
increase in apoptosis, inhibition of angiogenesis, creation of 
reactive oxygen species, loss of cytoskeletal control of tight 
junctions, increase in gastrointestinal permeability, and injury 
to blood vessels by an increase in adhesion molecules and 
injury to endothelial cells. A major source of NSAID injury 
is nonselective inhibition of the cyclo-oxygenase (COX) 
enzyme with resultant decreased production of prostaglandins. 
COX is the rate-limiting enzyme in the production of pros-
taglandins from arachidonic acid. Two isoforms have been 
identified, ie, COX-1 which is expressed constitutively 
and involved heavily in gastric mucosal integrity and the 
mucus barrier, and COX-2 which is inducible and found in 
areas of inflammation. Prostaglandin E2 (PGE2) induces 
protection by stimulating release of bicarbonate and mucus. 
The   bicarbonate stimulatory effect of PGE2 is mediated by 
endogenous prostaglandin (EP)-1 receptors coupled with Ca2+ 
along the gastric mucosa, and EP-3 and EP-4 coupled intrac-
ellularly with Ca2+ and cyclic AMP in the duodenal mucosa.1,2 
As such, prostaglandin analogs, misoprostol, H2-receptor 
antagonists (H2RA), and proton pump inhibitors have been 
evaluated in randomized controlled trials for the prevention 
of chronic NSAID-induced upper gastrointestinal toxicity. 
In a meta-analysis of these trials, misoprostol significantly 
reduced the risk of endoscopically visualized ulcers with a 
dose-response relationship in prevention of gastric ulcers 
at 400 µg and 800 µg daily (relative risk [RR] 0.17 and 
0.39, respectively, P = 0.0055). Misoprostol resulted in a 
reduction in risk of ulcer complications also, but resulted in 
diarrhea at all doses. Standard doses of H2RAs reduced the 
risk of endoscopic duodenal ulcer (RR 0.36; 95% confidence 
interval [CI] 0.18–0.74) but not gastric ulcers (RR 0.73; 
95% CI 0.50–1.08). Double-dose H2RAs and proton pump 
inhibitors were effective at reduction of endoscopic duodenal 
and gastric ulcers (RR 0.44; 95% CI 0.26–0.74 and RR 0.40; 
95% CI 0.32–0.51, respectively, for gastric ulcer). These 
agents were better tolerated than misoprostol.3
The effect of NSAIDs on gastric secretory physiology is 
incompletely understood. Twenty-four hour gastric pH stud-
ies have shown a lower mean 24-hour pH. There are several 
possible explanations for this observation, including 
stimulation of gastric acid secretion. In a study of gastric acid 
secretory function, 24 patients were evaluated after one week 
of naproxen 500 mg twice daily. Pentagastrin stimulation did 
not change maximum acid secretion. However, the gastric pH 
was lower in the basal acid secretion period, with no change 
in the number of mEq of acid secreted per hour. The basal 
total volume was decreased, suggesting that the reason the pH 
was lower is secondary to a naproxen-induced decrease in the 
nonacid fluid volume.4 Suppression of the acid mEq would, 
therefore, result in a re-established normal gastric pH. The 
gastroprotective effects of proton pump inhibitors, working 
through decreasing acid secretion by inhibition of the H+-K+-
ATPase of the parietal cell, are more potent than other acid 
suppression classes. In addition to acid suppression, proton 
pump inhibitors have been noted to reduce oxidative stress 
by the induction of heme oxygenase-1.5 Proton pump inhibi-
tors have been shown to increase the strength of the gastric 
mucus barrier significantly6,7 and to inhibit neutrophil-derived 
oxygen free radical species.8,9 In a large-scale randomized 
comparison of twice-daily esomeprazole 20 mg and 40 mg 
with twice-daily ranitidine 150 mg in Helicobacter pylori-
negative patients with documented NSAID ulcers continuing 
to take NSAIDs, ulcer healing was seen in 85.7%, 84.8%, 
and 76.3%, respectively, at eight weeks.10 Another study 
evaluated 350 patients with NSAID-related gastric ulcers 
who continued to use NSAIDs, and 73% of patients given 
lansoprazole 30 mg daily had ulcer healing at eight weeks 
compared with 69% of patients on lansoprazole 15 mg daily 
and 53% of patients on ranitidine 150 mg twice daily.11
Prevention of gastroduodenal ulcer recurrence with 
esomeprazole has been evaluated in high-risk patients 
with a history of peptic ulcer disease, aged over 60 years, 
and taking nonselective NSAIDs and COX-2 inhibitors. 
This was performed as two similar, double-blind, placebo-
controlled, randomized, multicenter studies in the US and 
internationally. In the US study, the proportion of patients 
who developed ulcers over six months was 20.4% with 
  placebo, 5.3% with esomeprazole 20 mg daily, and 4.7% with 
esomeprazole 40 mg daily. In the international study, peptic 
ulcer disease recurrence was seen in 12.3% on placebo, 5.2% 
on esomeprazole 20 mg, and 4.4% on esomeprazole 40 mg. 
Esomeprazole was effective in preventing ulcers in both the 
nonselective NSAID and COX-2 inhibitor groups. Of note, 
this study, like similar ones, demonstrates that esomeprazole 
20 mg daily is an effective dose for ulcer prevention in long-
term NSAID users.12Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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Risk of peptic ulcer disease
In the framework of discussing the risk of peptic ulcer   disease 
and its complications attributed to NSAIDs, a number of 
factors that alter the degree of risk are important. A history 
of previous peptic ulcer disease, presence of H. pylori, 
smoking, alcoholism, increased age, and concomitant use of 
corticosteroids, aspirin, other NSAIDs, and warfarin, are all 
important and increase the risk of peptic ulcer disease. While 
H. pylori is the cause of the majority of gastric and duodenal 
ulcers, aspirin and NSAIDs continue to be a common source, 
accounting for approximately 15% of duodenal ulcers and 
26% of gastric ulcers.13 In an endoscopic study of chronic 
diclofenac users with rheumatoid arthritis or osteoarthritis, 
24% of patients had gastric or duodenal ulcers.14 Regular 
NSAID usage occurs in 11% of the US population, which 
increases the odds of gastrointestinal bleeding five- to six-fold 
compared with those not taking NSAIDs.15,16 Some 1%–4% 
of NSAID users have serious ulcer-related complications 
every year.17 In many cases, life-threatening complications 
may be the first manifestation of peptic ulcer disease, as seen 
in a study of 235 patients, of whom 58% had previously been 
without symptoms.18 There is evidence that the individual 
NSAID may correlate with the risk of bleeding. This was seen 
in a case-control study of 2777 patients, with the highest risk 
of bleeding seen for ketorolac.19
Gastrointestinal safety and tolerability studies demonstrate 
that COX-2 inhibitors provide a significant risk reduction of 
gastroduodenal ulcers, ulcer complications, and gastroin-
testinal symptoms compared with traditional nonselective 
NSAIDs. The benefit of the COX-2 relative risk of ulcers 
(0.26) and ulcer complications (0.39) was significantly 
reduced when taken concomitantly with aspirin.20 The 
  disrupted benefit of COX-2 by aspirin is felt to be the 
  reason that no significant difference was seen in CLASS 
(the   Celecoxib Long-Term Arthritis Safety Study) with 
regard to the incidence of ulcer complications between 
  celecoxib and the nonselective NSAID group.21 This was 
better   delineated in TARGET (the Therapeutic Arthritis 
Research and   Gastrointestinal Event Trial) in which age and 
low-dose aspirin groups were stratified. The significantly 
reduced incidence of ulcer complications in the lumiracoxib 
group compared with nonselective NSAIDs was negated in 
the low-dose aspirin study arm.22
Risk of cardiovascular events
Despite the reduced gastrointestinal toxicity and improved 
safety profile of the COX-2 inhibitors, the increased 
cardiovascular risk has created appropriate hesitation in the 
use of these agents. During a study comparing   rofecoxib 
with naproxen, the incidence of acute myocardial infarction 
was four times higher in the COX-2 inhibitor group.23 
  Cardiovascular safety was next analyzed by deriving from 
data in the two long-term studies of colon polyp prevention 
with rofecoxib, ie, the APPROVE (Adenomatous Polyp 
Prevention on Vioxx) study and celecoxib, ie, the APC 
(Adenoma Prevention with Celecoxib) study. In the 
APPROVE study, 18-month interim data indicated that 
patients receiving rofecoxib 25 mg daily had twice the risk 
of serious cardiovascular events compared with patients 
receiving placebo.24 In the APC study, interim data at 
33 months showed an occurrence of serious cardiovascular 
events significantly higher at the very high dose of 400 mg 
twice daily only.25
Thereafter, traditional, nonselective NSAIDs were 
analyzed to examine for additional cardiovascular safety 
concerns. With the exception of full-dose naproxen (1000 mg 
a day), they also carry an increased cardiothrombotic risk. In a 
meta-analysis evaluating the risk of COX-2 inhibitors and 
nonselective NSAIDs, Kearney et al found that both groups 
of medications increased the risk of serious cardiovascular 
events more than placebo and naproxen. COX-2 inhibitors had 
a 42% relative increase in the incidence of serious   vascular 
events compared with placebo, with no significant heteroge-
neity between the different selective COX-2 inhibitors, attrib-
uted mainly to an increased risk of myocardial infarction. 
Overall, the incidence of serious   vascular events was similar 
between a selective COX-2 inhibitor and any traditional 
NSAID. Compared with placebo, the summary rate ratio for 
vascular events was 0.92 for naproxen, 1.51 for ibuprofen, 
and 1.63 for diclofenac.26
Enteric-coated naproxen + 
esomeprazole combination
In light of the cardiovascular concerns, use of naproxen for 
chronic rheumatologic disorders will likely become more 
prevalent. Because proton pump inhibitor therapy has been 
shown to be an efficacious approach in reducing NSAID-
associated gastrointestinal injury, its use is recommended as 
a current prevention strategy. Despite this, gastroprotective 
treatments are underprescribed by providers, prescribed at 
suboptimal doses, or suffer from patient nonadherence result-
ing in worsened clinical outcomes.27 PN400 is a fixed-dose 
combination formulation designed to provide sequential 
delivery of a nonenteric-coated, immediate-release esome-
prazole 20 mg mantle followed by an enteric-coated naproxen 
500 mg core.Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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A crossover, open-label, single-center Phase I study 
comprising four treatment periods was performed in which 
patients were randomized into one of four treatment sequences 
for nine days, with a washout period of $14 days between 
treatments. Patients were healthy adults aged 18–55 years 
without prior history of peptic ulcer disease and who had 
tested negative for H. pylori. Twenty-eight patients were 
randomized and included in the safety, pharmacokinetics, 
and intention-to-treat populations. Twenty-seven patients 
completed the study, and 25 were included in the per-protocol 
population. Enteric-coated naproxen 500 mg coupled with 
immediate-release esomeprazole 30 mg, 20 mg, and 10 mg 
(PN400/E30, PN400/E20, and PN400/E10, respectively) 
twice daily comprised three of the treatments. The fourth 
treatment was nonenteric-coated naproxen 500 mg twice 
daily and esomeprazole 20 mg daily. The study medication 
was administered 60 minutes prior to meals in the morning 
and evening. On day 9, esomeprazole had a corresponding 
dose-related effect on gastric pH beyond the influence of 
food intake. After administration of morning PN400 doses, 
rapid, dose-related increases in pH were seen approximately 
one hour earlier than food-induced increases in pH. On the 
contrary, a delay in increased pH was seen following morning 
administration of naproxen and esomeprazole 20 mg. After 
nine days of treatment, PN400/E30 and PN400/E20 had 
similar effects on gastric pH resulting in a slower return to 
low pH after food consumption compared with PN400/E10 
and naproxen and esomeprazole 20 mg. While initial doses of 
esomeprazole had only minimal effect on gastric pH beyond 
the effect of food intake, treatment differences emerged after 
the second dose.
Pharmacodynamic studies demonstrated several 
interesting features. On day 1, measurable plasma 
concentrations of esomeprazole were obtained rapidly with 
all three PN400 treatments at 10 minutes after the morning 
dose and 20–30 minutes after the evening dose. It was 
rapidly eliminated from plasma in the majority of subjects 
by 6–8 hours after the dose from all three PN400 treatments. 
Regarding naproxen, plasma concentrations on day 1 were 
first detected at approximately two hours following PN400 
administration for all three treatment groups. On day 9, 
premorning dose samples showed measurable esomeprazole 
concentrations in 19 patients at the PN400/E30 dose, 
13 patients at the PN400/E20 dose, and six patients at the 
PN400/E10 dose. Analyses after the morning and evening 
doses showed that for the PN400 treatments with higher 
esomeprazole doses (PN400/E30 and PN400/E20), plasma 
concentrations of esomeprazole were measurable at earlier 
time points after dosing in a large number of patients and for a 
longer period of time compared with day 1. Samples before the 
morning dose showed measurable naproxen concentrations 
throughout the various sampling times. On day 9, all 
subjects had measurable naproxen concentrations before the 
morning dose. Following the morning and evening doses on 
days 1 and 9, plasma esomeprazole concentrations increased 
with the esomeprazole dose for all three PN400 treatments. 
Maximum plasma concentrations for naproxen occurred after 
approximately 3–4 hours and was higher after the morning 
dose than after the maximal evening dose at 10–14 hours on 
day 1 and day 9 for all three PN400 treatments. Following 
treatment with esomeprazole 20 mg and nonenteric-coated 
naproxen, naproxen was quickly absorbed, with peak plasma 
concentrations observed at 1.5 hours postdose on days 1 and 
9 in the majority of subjects, and were measurable for longer 
than concentrations following PN400 administration. This 
plasma esomeprazole profile was consistent with a delayed-
release formulation. Mean plasma profiles of naproxen were 
comparable following the three PN400 treatments which is 
consistent with the delayed-release formulation. Higher mean 
naproxen plasma concentration levels observed at the end of 
a 24-hour daily interval are the result of a delayed absorption 
of naproxen from PN400. Mean plasma concentrations of 
naproxen were much higher on day 9 than day 1. Following 
treatment with naproxen and esomeprazole 20 mg on day 1, 
plasma naproxen concentrations were measurable in all 
subjects at the 10-minute postdose sample time and for up 
to 24 hours thereafter, which is consistent with a nonenteric-
coated naproxen formulation. After morning and evening 
doses on days 1 and 9, mean plasma naproxen concentrations 
were higher and occurred earlier following naproxen with 
enteric-coated esomperazole 20 mg than any of the PN400 
treatments.
The pharmacokinetic parameters of PN400 following 
administration of the morning and evening doses on days 
1 and 9 are summarized in the Table 1. Peak esomeprazole 
plasma concentrations occurred approximately 0.5 hours 
after the morning dose, and between 1.0–1.5 hours after 
the evening dose on days 1 and 9 for all three PN400 
treatments. Peak naproxen plasma concentrations occurred 
approximately 3–4 hours after the morning dose, and between 
10–14 hours after the evening dose on days 1 and nine for all 
three PN400 formulations. The delay in naproxen absorption 
is consistent with the enteric-coated naproxen in PN400. Peak 
plasma esomeprazole concentrations and areas under the 
concentration-time curve were higher following the morning 
dose than the evening dose on days 1 and 9 for all three Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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PN400 treatments and were dose-dependent. Esomeprazole 
concentrations were higher on day 9 than day 1 for each 
PN400 treatment. Peak plasma naproxen concentrations and 
areas under the concentration-time curve after the morning 
and evening doses were comparable among all three PN400 
treatments, expected with the same dose of naproxen in each 
formulation.28
Two Phase III studies (Study 301, n = 438 and Study 
302, n = 423) compared the upper gastrointestinal efficacy 
and safety of PN400 with enteric-coated naproxen alone in 
patients at risk of NSAID-associated ulcers. Evaluations 
were randomized, double-blind, controlled, parallel-group, 
multicenter studies with H. pylori-negative patients with 
osteoarthritis, rheumatoid arthritis, or another condition 
requiring chronic NSAIDs without baseline peptic ulcer dis-
ease aged $50 years or 18–49 years with a history of peptic 
ulcer disease in the past five years. Treatment was twice 
daily in both arms, and tolerability, safety, and endoscopic 
analysis were performed at baseline, at 30 and 60 days, and 
at six-monthly intervals thereafter. The primary endpoint 
of the studies was cumulative incidence of gastric ulcers, 
defined as a mucosal break $3 mm in depth throughout 
the six months of therapy. The analysis was designed for 
stratification by low-dose aspirin usage (#325 mg/day). 
Secondary endpoints included cumulative incidence of 
duodenal ulcers, discontinuation of the medication as a 
result of any adverse event, and incidence of prespecified 
NSAID-associated upper gastrointestinal adverse events 
and/or duodenal ulcers. Secondary endpoints also included a 
number of patient reported outcomes which will be discussed 
later in the tolerability section.
In Study 301, the cumulative incidence of gastric ulcers 
in the PN400 arm was 4.1% compared with 23.1% in the 
enteric-coated naproxen arm. Similarly, in Study 302, a 
significant reduction of gastric ulcers was seen in 7.1% of 
PN400 patients relative to 24.3% of naproxen patients. The 
incidence of discontinuations from the study secondary to 
NSAID-associated upper gastrointestinal adverse events or 
duodenal ulcers was significantly less in PN400 patients. 
In Study 301, this included 3.2% compared with 12% in 
the enteric-coated naproxen arm (P , 0.001). In Study 302, 
4.8% of PN400 patients discontinued for these reasons, along 
Table 1 Pharmacokinetics of naproxen + esomeprazole combinations*
Treatment, day  
and dose
Esomeprazole Naproxen
Cmax (ng/mL) tmax (h) AUC (h*ng/mL) Cmax (ng/mL) tmax (h) AUC (h*ng/mL)
PN 400/e30 (n = 28)
Day 1, morning 487 (82) 0.50 (0.33–1.50) 591 (108) 48.1 (53) 4.00 (2.00–10.00) 259 (56)
Day 1, evening 187 (132) 1.50 (0.33–4.00) 388 (137) 68.9 (28) 14.00 (0.50–14.00) 471 (30)
PN 400/e20 (n = 28)
Day 1, morning 292 (77) 0.50 (0.20–1.50) 350 (113) 44.4 (68) 4.00 (2.00–10.00) 231 (70)
Day 1, evening 96.6 (104) 1.49 (0.33–3.00) 206 (141) 71.5 (26) 14.00 (0.00–14.00) 450 (33)
PN 400/e10 (n = 27)
Day 1, morning 138 (71) 0.33 (0.17–3.10) 148 (111) 57.0 (31) 4.00 (2.00–10.00) 310 (35)
Day 1, evening 35.3 (84) 1.50 (0.33–3.00) 85.7  (179) 68.6 (26) 10.00 (0.00–14.00) 508 (29)
Naproxen + enteric-coated  
e20 (n = 28)
Day 1, morning 282 (66) 1.50 (1.00–16.00) 540  (60) 65.5 (25) 1.50 (0.75–6.00) 409 (16)
Day 1, evening 81.5 (14) 1.50 (0.50–2.50) 685 (10)
PN 400/e30 (n = 28)
Day 9, morning 1584 (39) 0.50 (0.17–1.50) 2779 (45) 80.9 (23) 3.00 (0.00–8.00) 603 (21)
Day 9, evening 810 (59) 1.00 (0.33–8.00) 2066 (53) 76.2 (23) 10.40 (0.00–14.00) 648 (20)
PN 400/e20 (n = 27)
Day 9, morning 715 (52) 0.50 (0.17–1.50) 1216 (69) 86.2 (22) 3.00 (0.00–8.05) 607 (19)
Day 9, evening 428 (73) 0.75 (0.33–3.00) 919 (84) 76.8 (18) 10.00 (0.00–14.00) 678 (16)
PN 400/e10 (n = 27)
Day 9, morning 278 (57) 0.33 (0.17–1.00) 368 (89) 87.1 (21) 2.50 (0.00–8.00) 637 (17)
Day 9, evening 976 (136) 1.00 (0.33–2.00) 223  (134) 78.6 (17) 14.00 (1.50–14.00) 672 (19)
Naproxen + enteric-coated 
e20 (n = 28)
Day 9, morning 435 (48) 1.50 (1.00–14.00) 1046 (54) 90.0 (19) 1.50 (0.50–4.00) 617 (12)
Day 9, evening 86.5 (13) 1.50 (0.75–4.00) 769 (10)
Notes: Values are mean (% coefficient of variation) for Cmax and AUC and medial (range) for tmax; *AUC0–10,AM or AUC0–14,PM  n = 26; *Reference 28.
Abbreviations: PK, pharmacokinetic; Cmax
, peak plasma concentration; tmax
, time to peak plasma concentration; AUC, area under the plasma concentration vs time curve. Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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with 11.9% in the naproxen group (P = 0.009). Importantly, 
evaluation of patients on low-dose aspirin also showed a 
protective benefit in the PN400 group, with a lower combined 
incidence of gastric ulcers (3.0%) versus enteric-coated 
naproxen (28.4%).27
Safety and tolerability
In the Phase I study, clinical adverse events (at least one) 
were reported in half of the patients in the PN400/E30 and 
PN400/E20 treatment groups (14/28). A third of patients on 
the PN400/E10 treatment were affected. Interestingly, only 
8/28 patients (29%) reported at least adverse event on the 
traditional naproxen with once-daily esomeprazole 20 mg 
treatment. In the further studied PN400/E20 formulation, 29% 
had adverse events in the form of gastrointestinal disorders, 
manifested as diarrhea (14%), abdominal distension (7%), 
and dyspepsia (7%). Of note, in this limited evaluation, upper 
abdominal pain and gastroenteritis were not demonstrated for 
the PN400/E20 treatment but were seen for the formulations 
with higher and lower esomeprazole doses (PN400/E30 and 
PN400/E10). Metabolism and nutrition disorders (18%), 
iron deficiency (18%), and headaches (4%) were also seen 
for the PN400/E20 treatment. No serious adverse events 
were reported, and no patient withdrew from the study due 
to adverse events.28
During the Phase III studies (301 and 302), safety was 
assessed by the incidence of adverse events, treatment-
related adverse events, and serious adverse events. These 
were assessed and captured throughout the trial by study 
personnel questioning, patient reporting of symptoms, 
physical examinations, laboratory assessments, and endo-
scopic findings. Clinical laboratory testing consisted of 
a hepatic function panel, blood urea nitrogen, creatinine, 
and complete blood count at screening and/or baseline and 
at months 1, 3, and 6. In the safety population, the overall 
incidence of treatment-emergent adverse events was similar 
between treatment groups in both studies (78% versus 
81.5% for Study 301; 76.2% versus 82.9% for Study 302). 
The most common treatment-emergent adverse events were 
gastrointestinal disorders seen in the form of patient-reported 
symptoms and/or endoscopic findings, which were more 
frequent in the enteric-coated naproxen group than in the 
PN400 groups.
The incidence of adverse events related to the study 
medication was higher with enteric-coated naproxen than 
PN400 in both studies. It is important to recognize that 
while a significant number of patients in the PN400 group 
had adverse events, many of these were endoscopic findings 
and did not correlate with patient symptoms. Adverse 
events were comparable between the study drug groups in 
the number of patients having an event with infections and 
infestations (16%–19%). In Study 302, the percentage of 
patients having an event related to nervous system disor-
ders (7.6%), musculoskeletal disorders (9.5%), and respi-
ratory, thoracic, and mediastinal disorders (4.8%) were 
identical between PN400 and enteric-coated naproxen. 
In Study 301, slightly fewer patients had problems in 
the enteric-coated naproxen group compared with the 
PN400 group in musculoskeletal disorders (6% versus 
8.3%) and nervous system disorders (4.2% versus 9.6%), 
likely related to headache.
In the category of gastrointestinal disorder-related 
adverse events, far fewer patients in the PN400 group had 
problems relative to enteric-coated naproxen (61.5% versus 
75% for Study 301; 60.5% versus 71.9% for Study 302). 
Far less esophagitis, erosive esophagitis, duodenitis, erosive 
duodenitis, erosive gastritis, upper abdominal pain, and 
dyspepsia were seen in the PN400 populations. Gastritis, 
diarrhea, nausea, and abdominal distension were variable 
between the studies, but fairly comparable overall, with 
a trend of benefit toward PN400. In Study 301, serious 
adverse events related to study treatment were duodenal ulcer 
hemorrhage (n = 1) and noncardiac chest pain (n = 1), in both 
the enteric-coated naproxen groups. No serious treatment-
related adverse events were present in Study 302, nor were 
there any deaths in either study.
With regard to tolerability, two subjective patient-recorded 
indices were utilized to assess upper gastrointestinal 
symptoms. The Severity of Dyspepsia Assessment 
(SODA) and Overall Treatment Evaluation of Dyspepsia 
(OTE-DP) scoring systems have been utilized in previous 
clinical trials.29,30 The SODA questionnaire was completed 
at baseline and at months 1, 3, and 6, and comprised 17 
questions measuring three categories of dyspepsia, ie, pain 
intensity, symptoms not related to pain, and satisfaction 
with dyspepsia-related health. The OTE-DP questionnaire 
is derived from the Global Ratings of Change questionnaire 
and was utilized at month 6 or at withdrawal. Patients 
with PN400 had significantly better upper gastrointestinal 
tolerability compared with those treated with enteric-coated 
naproxen in terms of SODA scores, proportion of heartburn-
free patients, and OTE-DP response. The change from 
baseline to six months in SODA scores in all three domains 
were dramatically in favor of PN400. In the pain intensity 
category, an average drop of 6.61 points compared with 0.16 
with enteric-coated naproxen (P , 0.001) in Study 301. Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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In Study 302, a drop of 2.84 over 0.08 was seen (P = 0.004). 
In nonpain symptoms, PN400 was superior (-2.18 
versus -0.47 in Study 301; -1.11 versus 0.11 for Study 302). 
Overall improvement of satisfaction scores increased by 3.36 
and 1.88 in the PN400 groups compared with 0.87 and 0.47, 
respectively, for Study 301 and Study 302. In the OTE-DP 
assessment, patients in both Study 301 and Study 302 noted 
better symptoms relative to baseline with PN400, and worse 
symptoms with enteric-coated naproxen.27
Implications for future work  
and improved patient care
Gastroprotective strategies, particularly with proton pump 
inhibitors, have been shown to prevent and reduce NSAID-
associated ulcers, ulcer complications, and bleeding, as well 
as NSAID-related heartburn and acid regurgitation. As the 
population ages, and the indications and usage of NSAIDs 
continue to climb, we must seek improved ways to be 
proactive in prevention of gastrointestinal toxicity. Adherence 
to gastroprotective agents by patients on chronic NSAIDs 
was less than 40% in two retrospective studies.31,32 For this 
reason, the need for improved physician and patient educa-
tion, strategies to improve patient compliance, and the use 
of a fixed-dose combination of NSAID and gastroprotective 
agent to target issues with compliance will all be key aspects 
for improved patient outcomes in the near future. No data 
exist to indicate that a proton pump inhibitor will reduce 
the complications of NSAIDs related to renal insufficiency, 
cardiovascular risk, and enteric or colonic complications, 
so more investigation into the risk and incidence of these 
complications is important. Some recent data raise concern 
that, while significant upper gastrointestinal toxicity from 
NSAIDs has diminished, lower gastrointestinal toxicity and 
events are on the rise. This has resulted in a calling for more 
comprehensive gastrointestinal endpoints, like the Clinically 
Significant Upper or Lower GI Events (CSULGIEs), as we 
examine these agents.33,34 It is certain that further work in 
traditional NSAID/gastroprotectant combinations and dif-
ferent selective inhibitor agents will occur.
Other combination therapies include diclofenac + 
misoprostol and ibuprofen + famotidine, which have also 
demonstrated a reduction in the endoscopic incidence of 
gastric ulcers. A subject of important debate is whether 
measurement of endoscopic ulcers as a primary endpoint 
is clinically important and valid. At this time, the evidence 
suggests that it is a reasonable and acceptable endpoint for 
clinical trials. While the data support the superiority of proton 
pump inhibitors over H2 blockers and prostaglandin analogs 
in the prevention of chronic NSAID-induced gastroduodenal 
ulcers, the only true determination of the relative efficacy 
would be a direct comparison study.
Conclusion
The choice of an anti-inflammatory agent and use of 
gastroprotection is an area of intense interest at this time, 
and requiring careful awareness of the individual patient’s 
history and risk for cardiovascular, cerebrovascular, and 
gastrointestinal events. The complexity of weighing these risk 
factors and making appropriate treatment recommendations 
is in a period of flux. Current recommendations are that 
patients with cardiovascular risk on aspirin who require 
NSAIDs should be treated with naproxen and a proton pump 
inhibitor for gastroprotection. For those patients with a risk 
of gastrointestinal bleeding but without cardiovascular risk 
factors, a COX-2 inhibitor or a nonselective NSAID with a 
proton pump inhibitor is recommended.35
While upper gastrointestinal events have been char-
acterized and studied extensively, the incidence of lower 
  gastrointestinal events and toxicity is poorly quantified. With 
an increase in lower gastrointestinal toxicity, study endpoints 
in the future will likely need to incorporate this to be able to 
counsel patients and select the appropriate agents. Further 
development of combination treatments will undoubtedly 
improve compliance and will reduce the risk of gastrointes-
tinal complications in chronic NSAID users.
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